2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 773

Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA
Abstract Number: 774

Anti-Nuclear Antibodies Have High Sensitivity for Systemic Lupus Erythematosus: Results of a Systematic Literature Review and Meta-Regression of Diagnostic Data
Abstract Number: 775

Identification of Candidate Items for Revised Classification Criteria for Systemic Lupus Erythematosus
Abstract Number: 776

Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies
Abstract Number: 777

SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®
Abstract Number: 778

Associations Between Autoantibodies and Clinical Manifestations in Systemic Lupus Erythematosus: Data from a Multiethnic Latin American Cohort
Abstract Number: 779

Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context
Abstract Number: 780

Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus
Abstract Number: 781

Anti-Nucleosome Antibodies Versus Anti-DNA Antibodies in the Diagnosis and Monitoring of Activity of Systemic Lupus Erytematosus
Abstract Number: 782

A Proposal for Assessing Systemic Lupus Erythematosus Activity By a Multimodal Instrument That Includes Clinical Variables, Physician Assessment and Modification of Treatment
Abstract Number: 783

Osteonecrosis in Systemic Lupus Erythematosus: Predictive Factors
Abstract Number: 784

Electronic Health Record (EHR) As a Powerful Tool to Establish Clinical Research Lupus Cohorts
Abstract Number: 785

Further Validation of Simple Index As a Simple Disease Activity Assessment Tool for SLE
Abstract Number: 786

Anti-Carbamylated Protein Antibodies Identify Systemic Lupus Erythematosus Patients with Erosive Arthritis: Analysis of a Regional Swedish Register
Abstract Number: 787

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].